^
    Back
    Association details:
    Biomarker:CCNE1 amplification
    Cancer:Ovarian Cancer
    Drug:BLU-222 (CDK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    (VELA) Study of BLU-222 in Advanced Solid Tumors

    Excerpt:
    ...Platinum refractory or platinum resistant ovarian cancer CCNE1 amplified tumors that have progressed beyond standard of care...
    Trial ID:
    VELA
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    2306 / 10 - BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models

    Published date:
    03/09/2022
    Excerpt:
    In vivo antitumor activity of BLU-222 as a single agent or in combination with carboplatin was measured in an OVCAR-3 cell line-derived xenograft (CDX) tumor model harboring a CCNE1 amplification....In a panel of ovarian cancer cell lines, those with CCNE1 amplifications were highly sensitive to BLU-222.